XW03306 - Introduction Peripheral Vein to New Technology Group 6 with Brexanolone, Percutaneous Approach
XW03308 - Introduction Peripheral Vein to New Technology Group 8 with Spesolimab Monoclonal Antibody, Percutaneous Approach
XW0332
XW03326 - Introduction Peripheral Vein to New Technology Group 6 with Nerinitide, Percutaneous Approach
XW0333
XW03336 - Introduction Peripheral Vein to New Technology Group 6 with Durvalumab Antineoplastic, Percutaneous Approach
XW0333A - Introduction Peripheral Vein to New Technology Group 10 with Bentracimab, Ticagrelor Reversal Agent, Percutaneous Approach
XW0334
XW0334A - Introduction Peripheral Vein to New Technology Group 10 with Cefepime-taniborbactam Anti-infective, Percutaneous Approach
XW0335
XW03357 - Introduction Peripheral Vein to New Technology Group 7 with Narsoplimab Monoclonal Antibody, Percutaneous Approach
XW03358 - Introduction Peripheral Vein to New Technology Group 8 with Mosunetuzumab Antineoplastic, Percutaneous Approach
XW0335A - Introduction Peripheral Vein to New Technology Group 10 with Ceftobiprole Medocaril Anti-infective, Percutaneous Approach
XW0336
XW03366 - Introduction Peripheral Vein to New Technology Group 6 with Lefamulin Anti-infective, Percutaneous Approach
XW03367 - Introduction Peripheral Vein to New Technology Group 7 with Terlipressin, Percutaneous Approach
XW03368 - Introduction Peripheral Vein to New Technology Group 8 with Afamitresgene Autoleucel Immunotherapy, Percutaneous Approach
XW0337
XW03372 - Introduction Peripheral Vein to New Technology Group 2 with Coagulation Factor Xa, Inactivated, Percutaneous Approach
XW03377 - Introduction Peripheral Vein to New Technology Group 7 with Trilaciclib, Percutaneous Approach
XW03378 - Introduction Peripheral Vein to New Technology Group 8 with Tabelecleucel Immunotherapy, Percutaneous Approach
XW0338
XW03387 - Introduction Peripheral Vein to New Technology Group 7 with Lurbinectedin, Percutaneous Approach
XW03388 - Introduction Peripheral Vein to New Technology Group 8 with Treosulfan, Percutaneous Approach
XW0338A - Introduction Peripheral Vein to New Technology Group 10 with Obecabtagene Autoleucel, Percutaneous Approach
XW0339
XW03396 - Introduction Peripheral Vein to New Technology Group 6 with Ceftolozane/Tazobactam Anti-infective, Percutaneous Approach
XW03398 - Introduction Peripheral Vein to New Technology Group 8 with Inebilizumab-cdon, Percutaneous Approach
XW0339A - Introduction Peripheral Vein to New Technology Group 10 with Odronextamab Antineoplastic, Percutaneous Approach
XW033A
XW033A6 - Introduction Peripheral Vein to New Technology Group 6 with Cefiderocol Anti-infective, Percutaneous Approach
XW033A7 - Introduction Peripheral Vein to New Technology Group 7 with Ciltacabtagene Autoleucel, Percutaneous Approach
XW033B
XW033B3 - Introduction Peripheral Vein to New Technology Group 3 with Cytarabine and Daunorubicin Liposome Antineoplastic, Percutaneous Approach
XW033B6 - Introduction Peripheral Vein to New Technology Group 6 with Omadacycline Anti-infective, Percutaneous Approach
XW033B7 - Introduction Peripheral Vein to New Technology Group 7 with Amivantamab Monoclonal Antibody, Percutaneous Approach
XW033BA - Introduction Peripheral Vein to New Technology Group 10 with Orca-T Allogeneic T-cell Immunotherapy, Percutaneous Approach
XW033C
XW033C6 - Introduction Peripheral Vein to New Technology Group 6 with Eculizumab, Percutaneous Approach
XW033C7 - Introduction Peripheral Vein to New Technology Group 7 with Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous, Percutaneous Approach
XW033CA - Introduction Peripheral Vein to New Technology Group 10 with Zanidatamab Antineoplastic, Percutaneous Approach
XW033D
XW033D6 - Introduction Peripheral Vein to New Technology Group 6 with Atezolizumab Antineoplastic, Percutaneous Approach
XW033DA - Introduction Peripheral Vein to New Technology Group 10 with Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension, Percutaneous Approach
XW033E
XW033E5 - Introduction Peripheral Vein to New Technology Group 5 with Remdesivir Anti-infective, Percutaneous Approach
XW033E6 - Introduction Peripheral Vein to New Technology Group 6 with Etesevimab Monoclonal Antibody, Percutaneous Approach
XW033F
XW033F3 - Introduction Peripheral Vein to New Technology Group 3 with Other New Technology Therapeutic Substance, Percutaneous Approach
XW033F5 - Introduction Peripheral Vein to New Technology Group 5 with Other New Technology Therapeutic Substance, Percutaneous Approach
XW033F6 - Introduction Peripheral Vein to New Technology Group 6 with Bamlanivimab Monoclonal Antibody, Percutaneous Approach
XW033FA - Introduction Peripheral Vein to New Technology Group 10 with Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy, Percutaneous Approach
XW033G
XW033G5 - Introduction Peripheral Vein to New Technology Group 5 with Sarilumab, Percutaneous Approach
XW033G6 - Introduction Peripheral Vein to New Technology Group 6 with REGN-COV2 Monoclonal Antibody, Percutaneous Approach
XW033G7 - Introduction Peripheral Vein to New Technology Group 7 with Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic, Percutaneous Approach
XW033H
XW033H5 - Introduction Peripheral Vein to New Technology Group 5 with Tocilizumab, Percutaneous Approach
XW033H6 - Introduction Peripheral Vein to New Technology Group 6 with Other New Technology Monoclonal Antibody, Percutaneous Approach
XW033H7 - Introduction Peripheral Vein to New Technology Group 7 with Axicabtagene Ciloleucel Immunotherapy, Percutaneous Approach
XW033J
XW033J7 - Introduction Peripheral Vein to New Technology Group 7 with Tisagenlecleucel Immunotherapy, Percutaneous Approach
XW033K
XW033K7 - Introduction Peripheral Vein to New Technology Group 7 with Idecabtagene Vicleucel Immunotherapy, Percutaneous Approach
XW033K9 - Introduction Peripheral Vein to New Technology Group 9 with Sulbactam-Durlobactam, Percutaneous Approach
XW033L
XW033L6 - Introduction Peripheral Vein to New Technology Group 6 with CD24Fc Immunomodulator, Percutaneous Approach
XW033L7 - Introduction Peripheral Vein to New Technology Group 7 with Lifileucel Immunotherapy, Percutaneous Approach
XW033M
XW033M7 - Introduction Peripheral Vein to New Technology Group 7 with Brexucabtagene Autoleucel Immunotherapy, Percutaneous Approach
XW033N
XW033N7 - Introduction Peripheral Vein to New Technology Group 7 with Lisocabtagene Maraleucel Immunotherapy, Percutaneous Approach
XW033P
XW033P9 - Introduction Peripheral Vein to New Technology Group 9 with Glofitamab Antineoplastic, Percutaneous Approach
XW033Q
XW033Q5 - Introduction Peripheral Vein to New Technology Group 5 with Tagraxofusp-erzs Antineoplastic, Percutaneous Approach
XW033Q9 - Introduction Peripheral Vein to New Technology Group 9 with Posoleucel, Percutaneous Approach
XW033R
XW033R9 - Introduction Peripheral Vein to New Technology Group 9 with Rezafungin, Percutaneous Approach
XW033S
XW033S5 - Introduction Peripheral Vein to New Technology Group 5 with Iobenguane I-131 Antineoplastic, Percutaneous Approach
XW033W
XW033W5 - Introduction Peripheral Vein to New Technology Group 5 with Caplacizumab, Percutaneous Approach
